| Drug Name |
Nicorandil |
| Drug ID |
BADD_D01562 |
| Description |
Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs [T28]. Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload [A20325]. |
| Indications and Usage |
Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes. |
| Marketing Status |
approved; investigational |
| ATC Code |
C01DX16 |
| DrugBank ID |
DB09220
|
| KEGG ID |
D01810
|
| MeSH ID |
D020108
|
| PubChem ID |
47528
|
| TTD Drug ID |
D0O2SR
|
| NDC Product Code |
Not Available |
| UNII |
260456HAM0
|
| Synonyms |
Nicorandil | 2-Nicotinamidoethyl Nitrate | 2 Nicotinamidoethyl Nitrate | Nitrate, 2-Nicotinamidoethyl | 2-Nicotinamidethyl Nitrate | 2 Nicotinamidethyl Nitrate | Nitrate, 2-Nicotinamidethyl | SG-75 | SG 75 | SG75 | Ikorel | Adancor | Dancor |
